Anticorps Polyclonal de lapin anti-CYP7A1

CYP7A1 Polyclonal Antibody for WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain et plus (3)

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications

12

N° de cat : 18054-1-AP

Synonymes

CP7A, CYP7, CYP7A1, CYPVII, Cytochrome P450 7A1

---

Galerie de données de validation

• 

  WB analysis using 18054-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 18054-1-AP (CYP7A1 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

---

Applications testées

• Résultats positifs en WB: cellules HepG2, cellules HuH-7, cellules L02, cellules SMMC-7721

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:6000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 11 publications below
• IHC: See 1 publications below

Informations sur le produit

18054-1-AP cible CYP7A1 dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: rat, Humain, souris, Hamster
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: CYP7A1 Protéine recombinante Ag12572
• Nom complet: cytochrome P450, family 7, subfamily A, polypeptide 1
• Masse moléculaire calculée: 504 aa, 58 kDa
• Poids moléculaire observé: 58 kDa
• Numéro d’acquisition GenBank: BC101777
• Symbole du gène: CYP7A1
• Identification du gène (NCBI): 1581
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

CYP7A1 (Cytochrome P450 Family 7 Subfamily A Member 1), is a cholesterol 7alpha-hydroxylase, catalyzing the first and rate-limiting step in the neutral or classic pathway for bile acid biosynthesis. CYP7A1 is a postulated gene modifier of colorectal cancer risk and target for the therapeutic bile acid, ursodeoxycholic acid (UDCA). The CYP7A1 enzyme controls the rate-limiting step of the catabolism of cholesterol into bile acids in the liver.

Publications

Species	Application	Title
mouse	WB	Cell Mol Gastroenterol Hepatol; Endoplasmic Reticulum Stress Regulates Hepatic Bile Acid Metabolism in Mice.; Authors - Anne S Henkel
human	WB	Cell Mol Gastroenterol Hepatol; A Mitochondrial DNA Variant Elevates the Risk of Gallstone Disease by Altering Mitochondrial Function.; Authors - Dayan Sun
mouse	WB	J Ethnopharmacol; Multi-omics and chemical profiling approaches to understand the material foundation and pharmacological mechanism of Sophorae Tonkinensis Radix et Rhizome-induced liver injury in mice; Authors - Si-Wei Rao
MOUSE	WB	J Lipid Res; Hepatic Deletion of X-box Binding Protein 1 Impairs Bile Acid Metabolism in Mice.; Authors - Xiaoying Liu
mouse	WB	Toxicol Sci; Hepatic, metabolic and toxicity evaluation of repeated oral administration of SnS2 nanoflowers in mice.; Authors - Disi Bai
human	IHC	J Steroid Biochem Mol Biol; Bird's eye view analysis of in situ cholesterol metabolic pathways in breast cancer patients and its clinicopathological significance in their subtypes.; Authors - Shinkichi Kosaka